WO2019164192A1 - Film-forming pharmaceutical composition containing nonsteroidal anti-inflammatory analgesic active ingredient - Google Patents

Abstract

The present invention relates to: a pharmaceutical composition, which contains a nonsteroidal anti-inflammatory analgesic active ingredient (NSAID), is convenient to use because of the formation of a film during application to an affected part, allows absorption to be maximized, and has low skin irritation; and a preparation method therefor. A pharmaceutical composition according to the present invention allows a film to be rapidly formed during application to an affected part so as not to be sticky and get on clothes and the like, unlike a conventional preparation for external use, and thus is convenient to use. In addition, the composition can be easily applied to places, such as finger joints, the knees, and the elbows, where attaching adhesives such as plaster is difficult. Moreover, treatment efficiency can be maximized by remarkably increasing drug absorption from the formulation to the affected part and has low skin irritation, thereby enabling abnormal skin symptoms such as rubefaction to be minimized even when applied to the skin for a long time. Therefore, the present invention can provide a pharmaceutical composition which is effective and convenient to use by patients who expect analgesic and anti-inflammatory analgesic effects with respect to osteoarthritis, periarthritis of shoulder, muscular pain and peritenonitis symptoms.

Description

Film forming pharmaceutical composition containing nonsteroidal anti-inflammatory analgesic active ingredient

The present invention is a non-steroidal anti-inflammatory analgesic active ingredient that is directly applied to the affected area that requires analgesic, anti-inflammatory action to form a film is convenient to use and drug absorption into the skin is significantly increased to maximize the efficacy and significantly improved skin irritation It relates to a film-forming pharmaceutical composition comprising, and a method for producing the same.

Pain refers to uncomfortable sensations caused by stimulation of specific nerves with pain receptors, and is classified into headache, chest pain, abdominal pain, low back pain, and so on depending on the mechanism. Somatic pain, visceral pain And neurogenic pain.

Pain can be treated in a variety of ways depending on its cause. In particular, if the cause of pain is identified and it is determined that the onset of pain will be temporary or not significant, the symptomatic treatment that improves the quality of life by treating drugs that can alleviate pain (an analgesic) is implemented. It is desirable to.

Analgesic can be divided into narcotic or nonnarcotic analgesics. Narcotic analgesics are very effective, but they are not used for serious pain because of side effects such as hallucinations, addiction and constipation.

Non-narcotic analgesics can be divided into steroidal anti-inflammatory agents such as dexamethasone, prednisolone and methylprednisolone, and nonsteroidal anti-inflammatory agents such as acetaminophen, aspirin, indomethacin, diclofenac, pullulbiprofen, ketoprofen, ibuprofen and naproxen.

Most nonsteroidal anti-inflammatory drugs inhibit the production of PG (Prostaglandin) or TX (thromboxane) by inhibiting COX (cyclooxygenase), which is involved in the inflammatory response. Indicates. COX is divided into COX-1 and COX-2. COX-2 is mainly involved in inflammation, pain and fever, and COX-1 is involved in the secretion of gastrointestinal defense factors in the gastrointestinal tract. 2 Inhibition of analgesic, anti-inflammatory and antipyretic effects, but inhibition of defense factor production by COX-1 inhibition can cause gastrointestinal side effects such as bleeding, ulcers.

Nonsteroidal analgesics are administered by oral or topical administration, and when the pain is extensive and accompanied by fever, or when the pain is deep and the topical medication is not effective enough, oral administration Preferred, however, may cause gastrointestinal side effects as described above, the administration of which is preferably for a short time. The localized location of the pain, the deeply affected area can be expected to have sufficient effect by drug delivery to the skin, and the patients who need long-term administration or have gastrointestinal underlying diseases such as gastric ulcer can be administered topically. desirable.

Various formulations for topical administration of NSAIDs are commercially available.

Formulations such as plaster or cataplasma are advantageous for long-term application, since the drug is mixed with a pressure sensitive adhesive and the like and can be attached directly to the affected area with a certain area. However, there is a limitation in stretching and adhesiveness, there is a problem in that it is inconvenient to apply to a lot of movement such as elbow, knee and finger joints. In addition, when applied to a prominent site such as face or neck, the color of the formulation is much different from the skin color, so there is a disadvantage that aesthetically sensitive consumers cannot easily apply. In addition, the skin irritation may occur due to the skin seal of the pressure-sensitive adhesive when applying the formulation, there is a disadvantage that the skin or hair attached to the adhesive when the formulation is applied and may suffer. In addition, various permeation accelerators and pressure-sensitive adhesives have the disadvantage that often cause skin irritation in a closed environment.

Gel, ointment, and liquid formulations are applied to the surface of the skin to absorb the drug into the affected area to express the medicinal benefits. It has the advantage of being easy to be applied to areas of high movement such as elbows, knees and finger joints. In addition, there is an advantage that it is easy to apply to aesthetically sensitive areas because it is transparent. However, after applying the product, it is not completely dry and sticky, and the formulation is easily lost by physical contact such as contacting the cloth, and thus the drug efficacy is not sustained.

Topical anti-inflammatory drugs are known to have several orders of magnitude lower concentrations in tissues than oral administration. The causes are very small compared to the area of the gastrointestinal tract, and drug penetration through the skin is very low. Because.

Therefore, the development and manufacture of a product that delivers the drug to the skin tissue as well as when administered orally shows a good effect and reduces the systemic side effects such as gastrointestinal bleeding by topically administering the drug is a topical drug. It is an important task of those skilled in the art to develop.

In addition, it is not limited in form, such as gel or ointment, so it is easy to adhere to any curved part of the human body, and it is transparent and there is no aesthetic problem. In addition, the development of topical medicines with minimal skin irritation is also an important task for the skilled person.

Various attempts have been made to increase skin absorption of NSAIDs to suppress deep tissue pain or strong inflammatory responses to the same level as oral administration.

Korean Patent Registration No. 10-0288190 discloses a composition having increased absorption containing pyoxycam and containing lower alcohol, HPMC, Carbopol, dimethyl glycol monoethylether, oleic acid, and alkanolamine. have.

Japanese Patent Publication No. 2002-503914 discloses a composition containing diclofenac and containing C2 to C4 alkyl alcohol, short chain N-alkyl pyrrolidone, and long chain alkyl pyrrolidone.

Korean Unexamined Patent Publication No. 2011-012678 discloses a composition containing a nonsteroidal anti-inflammatory analgesic active ingredient and including a polyhydric alcohol, a polyoxyalkylene alkyl ether, and a polyoxyalkylene alkenyl ether, and having an improved analgesic effect.

Korean Patent Laid-Open Publication No. 1999-0082208 discloses a transparent aqueous solution of diclofenac sodium consisting of diclofenac sodium, dialkyrroleamide and water.

Korean Patent Laid-Open Publication No. 2015-0074009 discloses an O / W emulsion composition having improved stability and absorption including oxybenzone as a ketoprofen and light stability improving material.

Japanese Patent Publication No. 2014-208623 discloses a composition having increased absorption including diclofenac, monoterpene, lactic acid and polar oils.

Japanese Patent Publication No. 2015-189759 discloses a composition comprising diclofenac, tocopherol or a derivative thereof, lactic acid and menthol.

International Patent Publication No. 93/00873 discloses a composition having improved absorption by containing diclofenac and containing C10 to C12 alkyl esters as absorption accelerators.

Korean Patent Publication No. 2010-0083799 discloses a composition exhibiting high skin permeability and low systemic absorption of diclofenac diethylammonium salt including carbomer, stearyl alcohol and the like.

International Patent Publication No. 2008/049020 discloses a composition comprising diclofenac, dimethylsulfoxide, ethanol, glycerol and a thickener.

International Patent Publication No. 2007/102090 discloses a composition comprising diclofenac, N-lauroyl sarcosine, sodium octyl sulphate, methyllaurate, isopropyl myristate, oleic acid, glyceryl oleide and the like.

International Patent Publication No. 2004/017998 discloses a composition comprising diclofenac, water, ethanol, propylene glycol, carbomers, fatty acids for producing emulsions, and surfactants.

International Patent Publication No. 2004/030665 discloses a composition containing at least 4.2% of diclofenac sodium in high concentration and further containing oleyl alcohol and isopropyl alcohol.

As seen in the various prior documents listed above, there have been many attempts and efforts to prepare compositions with increased absorption. However, there is no disclosure of topical compositions that are readily used and have increased absorption by directly applying the film directly to the affected area.

Korean Patent No. 10-0190450 discloses a composition comprising a polyurethane film on the back layer and containing chitosan, a solvent, a dissolution aid, and an alkali metal salt of C16-C17 saturated or unsaturated fatty acid as an adhesive aid component. . However, the composition is inconvenient to apply to a variety of sites, such as a patch-shaped curved patch that is already defined in shape before applying to the affected area.

Korean Patent Laid-Open Publication No. 1998-076273 discloses a film forming polymer as polyethylene oxide; Sorbitol, mannitol, hyaluronic acid and allatoin as humectants; Ethanol and 2-propanol as water vaporization accelerators; Triethyl citrate as softener; Disclosed is a composition which minimizes the increase in foot edema, which contains polysorbate 80, oleic acid, and the like as a drug absorption accelerator, and contains various physiologically active ingredients such as ketoprofen and amikacin. However, the composition has a severe skin irritation, so when applied to the human skin abnormalities such as skin redness occurs, it is necessary to improve it.

As such, in order to increase the efficacy of topical anti-inflammatory drugs, many attempts have been made to use absorbent enhancers, change the solvent of the formulation, or refine the size of the drug. However, topical anti-inflammatory analgesics have been tried and developed without rapid skin irritation, with rapid drying of the formulation, film formation in the affected area, keeping the formulation strong from physical friction, and long lasting effects.

In order to facilitate the use and application of the nonsteroidal anti-inflammatory analgesic active ingredient, the present inventors quickly dry the film when applied to the affected area, and thus, there is no stickiness, and no drug is lost even when it touches physical friction or cloth, Formulations that can be attached have been studied for a long time, and as a result, the present invention has been completed.

The composition of the present invention not only has such ease of use, but also surprisingly, the drug permeability is remarkably superior compared to the existing commercial formulations and the skin irritation is remarkably improved compared to the inventions disclosed in the prior literature.

To date, only topical formulations have attempted to increase skin permeability in order to increase the effect on the affected area, and when applied to the affected area, the film can be formed instantly, which can be used on any part of the body and is not sticky and physically resistant to friction. Attempts have been made to produce formulations that are strong and retain the drug for a long time while at the same time having little skin irritation.

The present invention not only increases the ease of use as described above by immediately forming a film when applied to the affected area, but also significantly increases skin delivery of the drug and at the same time hardly causes skin irritation, the film-forming pharmaceutical composition, and a method of preparing the same. To provide that purpose.

In order to achieve the above object, the present invention provides a pharmaceutical composition to form a film immediately when applied to the affected area, improve the skin absorption and skin irritation of the drug, to maximize the ease of use and effect, and a method for preparing the same. .

The composition according to the invention comprises a) at least one nonsteroidal anti-inflammatory analgesic active ingredient or a pharmaceutically acceptable salt thereof, b) a film former, c) a C8 to C24 fatty alcohol, d) a C2 to C4 alcohol and e) an interface. It contains a activator and forms a film when applied to the affected area or skin.

The composition according to the invention comprises at least one nonsteroidal anti-inflammatory analgesic active ingredient. The nonsteroidal anti-inflammatory analgesic active ingredient (NSAID) is a generic name for a substance that inhibits COX without having a steroid structure, and includes, but is not limited to, the following active ingredients. It may be a free acid or a salt thereof, as the active ingredient itself, or a free acid or salt thereof, of an isomer thereof.

Salicylates: aspirin, dipulunisal, salicylic acid or derivatives thereof, salsalates, etc.

Propionic acid derivatives: ibuprofen, phenopropene, flubiprofen, dexibuprofen, ketoprofen, oxaprozin, naproxen, dexketoprofen, loxopropene

Acetic acid derivatives: indomethacin, sulindac, ketorolac, aceclofenac, tolmetin, etodolak, diclofenac, nabumentone

Oxycam derivatives: pyroxicam, tenoxycam, lornoxicam, phenylbutazone, meloxycam, doxycamp, isoxiccam

-Ansranilic acid derivatives: mephenamic acid, mecrofenamic acid, pullulatemic acid, tolpenamic acid

-Nimesulide, celecoxib, rofecoxib, valdecoxib, lumiracoxib

The composition of the present invention may comprise one or more nonsteroidal anti-inflammatory analgesic active ingredients, and it is preferable that the active ingredient is acidic when in the base form. The content of the active substance is in a concentration range in which the safety and effectiveness are found, and a range of 0.1 to 10 times the concentration in which each component is marketed is preferable.

The composition according to the invention comprises at least one film forming material. The film forming material volatilizes the solvent when applied to the skin to produce a film containing the active ingredient in the affected part. The film forming material prevents moisture evaporation of the skin and makes it wet, so that the connective tissue can be softened and increase the skin absorption of the active ingredient. It also forms a non-stick film to minimize the loss of formulation by physical contact.

The film forming material according to the present invention is hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, methyl cellulose, polyethylene oxide, polyvinylpyrrolidone; Methyl vinyl ether maleic acid copolymer or a salt thereof, or methyl, ethyl, isopropyl, butyl ester; Vinylpyrrolidone / vinylacetate copolymer, octylacrylamide copolymer, aminoalkyl methacrylate copolymer, amoniomethacrylate copolymer, ethylacrylate / methylmethacrylate copolymer, hydroxypropylmethylcellulose phthale Latex, or acetate succinate, polyvinyl alcohol, polyvinylacetate, polyoxyethylene glycol / polyvinylacetate graft copolymer, chitosan, polyvinylacetal diethylamino acetate. Preferably, the film forming material is chitosan, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl acetal diethylamino acetate polyoxyethylene glycol / polyvinylacetate graft copolymer or poly Vinyl alcohol.

The film forming material should contain a sufficient amount to form a film on the affected part, it is preferable to include 2 to 20% by weight based on the total weight of the composition.

The composition according to the present invention comprises at least one C8-C24 fatty acid alcohol, in order to maximize skin absorption of the nonsteroidal anti-inflammatory analgesic active ingredient. The C8-C24 fatty acid alcohol dissolves the nonsteroidal anti-inflammatory analgesic active ingredient, and after the volatile substances in the composition is volatilized, present the active ingredient which is insoluble in water in a dissolved state, whereby the formulation is dried to form a film. It can increase skin absorption of NSAIDs.

The C8 ~ C24 fatty alcohols are undecyl alcohol, lauryl alcohol, tridecyl alcohol, myristyl alcohol, pentadecyl alcohol, cetyl alcohol, palmitoyl alcohol, heptadecyl alcohol, stearyl alcohol, oleyl alcohol, nonadecyl alcohol, Arachidyl alcohol, behenyl alcohol, elusyl alcohol, and the like, but are not limited thereto. C8 to C24 fatty acid alcohol of the present invention may be included in one or a combination, it is preferable to include 0.1 to 10% by weight based on the total weight of the composition.

After the composition according to the invention is applied to the skin and the volatile solvent has evaporated, it comprises a surfactant which makes the active ingredient and C8 to C24 fatty alcohols present as fine particles. The surfactant may be a material generally known below.

Polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyethylene hydroxystearate (Solutol HS15), polyethoxylated castor oil (Cremophor EL, Cremophor RH40, Cremophor RH60), ethylene oxide / Propylene oxide copolymers (poloxamer 124, poloxamer 188, poloxamer 407), Gelucire 50/13, Gelicire 44/14, Labrfil, Capryol, Lauroglycol 90, Plurol Oleique, Labrafac, Maisine 35-1, Peceol, Transcutol, Nonionic Surfactants, such as Labrasol

-Ionic surfactants such as sodium lauryl sulfate, sodium docusate, benzalkonium chloride, benzetonium chloride

Preferably, the surfactant of the present invention may be a nonionic surfactant, specifically, hydroxystearate (Solutol HS15), polyethoxylated castor oil (Cremophor EL, Cremophor RH40, Cremophor RH60), ethylene oxide / propylene oxide Copolymers (poloxamer 124, poloxamer 188, poloxamer 407). The surfactant may be included in an amount of 0.005 to 10 parts by weight, and preferably 0.01 to 5 parts by weight, based on 1 part by weight of the active ingredient.

The composition according to the invention comprises a C2 to C4 alcohol. C2 ~ C4 alcohol dissolves the active ingredient to exist in a constant concentration, maximizes skin absorption of nonsteroidal anti-inflammatory analgesic active ingredients, and minimizes stickiness by rapidly evaporating and drying the composition when it is applied to the affected area It increases the ease of use.

The C2 to C4 alcohol may be ethanol, 1-propanol, 2-propanol, butanol, ethylene glycol, propene glycol, glycerol, allyl alcohol, and the like, but is not limited thereto. Preferably, the boiling point may be ethanol, 1-propanol or 2-propanol having a boiling point of 100 ° C. or less. The C2 ~ C4 alcohol may be included in 10 to 90% by weight, preferably 30 to 90% by weight relative to the total weight of the composition.

The composition according to the invention may comprise further additives in addition to the above materials. E.g. pH adjusters may be included. The pH adjusting agent may be used for the purpose of helping to dissolve the nonsteroidal anti-inflammatory analgesic active ingredient, to dissolve the cationic film-forming substance or thickener, or to maintain the preservation of the preparation from the microorganism. PH adjusters that may additionally be included in the compositions of the present invention may include materials and amounts typically used in the art.

The composition according to the present invention may include an additional solvent, in addition to the C2 ~ C4 alcohol. Additional solvents may be added in consideration of skin moisturizing, active ingredient solubility, film forming agent or thickener solubility, the type and amount may be included to the extent generally known in the art.

Compositions according to the invention may further comprise plasticizers, surfactants, co-solvents, preservatives, flavoring agents and the like.

The types and amounts of additional compositions according to various functions that may be included in the compositions of the present invention are specifically illustrated and listed in Handbook of Pharmaceutical Excipients 7 ^th edition by Raymond C. Rowe.

The present invention provides the following effects.

First, the composition according to the present invention, when directly applied to the affected area, quickly forms a film, not as sticky as the conventional external preparation, easy to use because it does not adhere to cloth and the like.

Second, the composition according to the present invention is free in terms of shape compared to plaster or cataplasmase, and can be easily applied to a lot of flexion and movement such as fingers, knees and elbows.

Third, by increasing the absorption of the nonsteroidal anti-inflammatory analgesic active ingredient to increase the therapeutic effect, it can maintain the effect for a long time by maintaining the drug.

Fourth, almost no skin irritation can be applied to the skin for a long time.

Figure 1 shows the skin permeability of Example 1 (100mg and 14.2mg) and Comparative Example 1.

Figure 2 shows the skin permeability of Examples 1, 7, 8, 11, 12, 14 and 19 and Comparative Examples 2 to 4.

Figure 3 shows the change in edema size in the arthritis animal model of the untreated group, Example 1, Comparative Examples 1 and 3.

Figure 4 shows the skin irritation of Examples 1 and 16, and Comparative Example 4.

Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited by the following examples.

Example 1-6

Preparation of a composition comprising various nonsteroidal anti-inflammatory analgesic active ingredients

According to the components and contents (% by weight) shown in Table 1 below, compositions containing various nonsteroidal anti-inflammatory analgesic active ingredients were prepared.

Ethanol, monoethanolamine, benzyl alcohol, oleyl alcohol, polyethoxylated castor oil (Koliphor EL), and hydroxypropylmethylcellulose were added to the nonsteroidal active ingredient, and the mixture was stirred by a paddle mixer. After hydroxypropyl cellulose was added to purified water and dispersed for 5 minutes with a Homomixer, the ethanol solution containing the active ingredient was added, followed by Homomixing and degassing under reduced pressure.

As a result of applying the composition of Examples 1 to 6 prepared as described above on the skin, it was dried after a few minutes to form a thin film and there was no stickiness on the surface.

	Example 1	Example 2	Example 3	Example 4	Example 5	Example 6
Ketoprofen	3	-	-	-	-	-
Diclofenac Sodium	-	One	-	-	-	-
Pullulbiprofen	-	-	5	-	-	-
Lysopropene sodium	-	-	-	One	-	-
Piroxycam	-	-	-	-	5	-
Ibuprofen	-	-	-	-	-	5
Hydroxypropylmethylcellulose	3	2	15	3	One	5
Hydroxypropyl cellulose	5	4	3	3	5	One
Propylene glycol	4	4	4	4	4	4
Oleyl alcohol	One	One	3	One	3	3
Benzyl alcohol	0.5	0.5	0.5	0.5	0.5	0.5
Monoethanolamine	One	One	One	One	One	One
Koliphor EL	0.1	One	3	One	3	3
ethanol	60	50	65	55	70	75
Purified water	Quantity	Quantity	Quantity	Quantity	Quantity	Quantity
Final weight 100g
Film	O	O	O	O	O	O

[Example 7-13]

Preparation of Compositions Including Various Film Forming Polymers

According to the components and contents (% by weight) shown in Table 2 below, compositions comprising various film forming polymers were prepared.

Ethanol or isopropyl alcohol, Koliphor EL, oleyl alcohol, benzyl alcohol, propylene glycol, and lactic acid or monoethanolamine were added to the nonsteroidal active ingredient and stirred by mixing with a paddle mixer.

In the case of Example 7, the chitosan was added to purified water, followed by Homomixing, the mixture was mixed with the mixed solution, followed by Homomixing, and purified water was added to make 100 g of the composition of Example 7.

In the case of Examples 8 to 13, each of the indicated film-forming materials of the mixed solution was added to form a gel by Homomixing, and purified water was added to 100 g to prepare the compositions of Examples 8 to 13.

As a result of applying the composition of Examples 7-13 prepared as described above to the skin, it dried after a few minutes to form a thin film and there was no stickiness on the surface.

	Example 7	Example 8	Example 9	Example 10	Example 11	Example 12	Example 13
Ketoprofen	3	3	3	3	3	3	3
Chitosan	3	-	-	-	-	-	-
Hydroxyethyl cellulose	-	3	-	-	-	-	-
Hydroxypropyl cellulose	-	-	12	-	One	One	One
Hydroxypropyl Methyl Cellulose	-	-	5	4	-	-	-
Polyvinyl acetal diethylamino acetate	-	-	-	-	5	-	-
Polyvinylacetate Graft Copolymer	-	-	-	-	-	5	-
Polyvinyl alcohol	-	-	-	-	-	-	5
Propylene glycol	2	3	4	5	3	4	2
Oleyl alcohol	0.5	One	2	2	2	2	2
Benzyl alcohol	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Lactic acid	One	-	-	-	-	-	-
Monoethanolamine	-	One	One	One	One	One	One
Koliphor EL	0.05	0.1	One	One	One	One	One
Isopropyl Alcohol	-	-	-	60	82	-	-
ethanol	45	45	65	-	-	65	65
Purified water	Quantity	Quantity	Quantity	Quantity	Quantity	Quantity	Quantity
Final weight 100g
Film	O	O	O	O	O	O	O

Example 14-19

Preparation of composition containing C8-C24 fatty alcohol

According to the component and the content (% by weight) shown in Table 3 below, a composition comprising a C8-24 fatty alcohol was prepared.

First, add the nonsteroidal active ingredient to ethanol, add one or more of Koliphor EL, Koliphor RH40, Koliphor RH60, Poloxamer 407, and Polysorbate8, add propylene glycol, propylparaben and monoethanolamine, and use a paddle mixer for 10 minutes. It mixed and stirred. In addition, one of the C8 ~ C24 fatty acid alcohol, and lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol and behenyl alcohol corresponding to each embodiment and mixed by stirring for 10 minutes with a paddle mixer Then, hydroxypropyl methyl cellulose was added and homomixed, followed by dispersion mixing for 30 minutes. Separately, after dissolving hydroxypropyl cellulose in purified water, the ethanol solution prepared above was mixed and homomixed for 1 hour to prepare the pharmaceutical compositions of Examples 14-19.

When the compositions of Examples 14 to 19 were applied to the skin, they dried after a few minutes to form a thin film and there was no stickiness on the surface.

	Example 14	Example 15	Example 16	Example 17	Example 18	Example 19
Ketoprofen	3	3	3	3	3	3
Lauryl Alcohol	2	-	-	-	-	-
Myristyl Alcohol	-	2	-	-	-	-
Cetyl alcohol	-	-	One	-	-	-
Stearyl alcohol	-	-	-	One	-	-
Oleyl alcohol	-	-	-	-	One	-
Behenyl Alcohol	-	-	-	-	-	One
Hydroxypropylmethylcellulose	3	3	3	3	3	3
Hydroxypropyl cellulose	3	3	3	3	3	3
Monoethanolamine	One	One	One	One	One	One
Koliphor EL	0.3	-	-	-	-	0.1
Koliphor RH40	-	0.3	-	-	-	-
Koliphor RH60	-	-	0.3	-	-	-
Poloxamer 407	-	-	-	0.5	0.5	0.1
Polysorbate 80	-	-	-	0.1	0.1	0.1
Propylene glycol	3	3	3	3	3	3
Propylparaben	0.1	0.1	0.1	0.1	0.1	0.1
ethanol	60	65	65	65	65	68
Purified water	Quantity	Quantity	Quantity	Quantity	Quantity	Quantity
Final weight 100g
Film	O	O	O	O	O	O

Comparative Example 1-5

Ketotopplasta (Handok), Kenofengel (Ildong Pharmaceutical Co., Ltd.), and Ketotopgel (Handok), which are commercially available products, were prepared as Comparative Examples 1 to 3.

In addition, the composition of the Republic of Korea Patent Application Publication No. 10-1998-0076273 was prepared as in Table 4 to the Comparative Example 4, and changed to the oleic alcohol in Example 1 to Comparative Example 5.

ingredient	Comparative Example 4
Ketoprofen	3 g
Polyethylene oxide	5 g
2-propanol	10 g
Sorbitol	0.5g
Hyaluronic acid	0.5 g
Triethyl citrate	2 g
Dimethylphthalate	0.1g
N-methyl-2-pyrrolidone	3 g
Polysorbate 80	1 g
Oleic acid	0.5 g
Polyol polymer	0.5g
Purified water	20 g

Experimental Example 1

Skin Permeability Comparison Experiment for Comparative Example 1

The skin of the hairless rat was taken, cut into a certain area, mounted in a Franz diffusion cell, and filled with pH 7.4 PBS in the receptor portion.

The formulation of Comparative Example 1 was cut to a certain size and attached to the skin of a donor cell. In Example 1, 100 mg or 14.2 mg of the same drug as a ketotop patch was injected and spread evenly in a donor cell. The liquid was collected from the receptor at regular intervals for 12 hours and HPLC analysis was performed to evaluate the degree of penetration of the drug per hour and skin area per skin (Flux, μg / cm 2 / h).

As shown in Figure 1, the composition of the present invention can be seen to significantly increase the permeability of the nonsteroidal anti-inflammatory analgesic active ingredient, compared to the patch of Comparative Example 1.

Experimental Example 2

Skin permeability comparison experiment for Comparative Examples 2 to 4

After applying the composition of Examples 1, 7, 8, 11, 12, 14 and 19 and 100mg of the composition of Comparative Examples 2 to 4 to the donor cell in the same manner as in Example 1, for 12 hours The degree to which the drug penetrates the skin at regular intervals (Flux, μg / cm 2 / h) is measured and shown in FIG. 2. As shown in Figure 2, the composition of the present invention was confirmed to significantly increase the permeability of the nonsteroidal anti-inflammatory analgesic active ingredient 2-3 times or more, compared to the gel products of Comparative Examples 2 and 3, which are commercial products.

In addition, as shown in Figure 2, the composition of the present invention was confirmed to significantly increase the permeability of the nonsteroidal anti-inflammatory analgesic active ingredient compared to Comparative Example 4 of the composition of the existing patent invention.

Experimental Example 3

Experiment of edema size reduction in arthritis animal

SD rats were anesthetized using Isoflurane, and monosodium iodoacetate was injected into the joint cavity of one hind limb to induce edema. Example 1, and Comparative Examples 1 and 2 were treated for 3 days to measure the difference in the thickness of the knee between the edema-induced leg and non-induced leg to confirm the extent to which the drug reduces edema is shown in Figure 3 It was.

As shown in Figure 3, it can be seen that the composition of the present invention shows a rapid effect on the first day of treatment, it was confirmed that the effect is superior to the untreated group.

3, the composition of this invention shows that the patch agent of the comparative example 1 which is a commercial product, and the comparative example 3 show the outstanding edema reduction effect also compared with a gel product.

Comparative Example 1 was less effective in reducing the edema on day 2 than the treatment day 1, Comparative Example 3 was found to take a long time to express the effect because the difference in the edema reduction effect between the treatment 1 and 2 days.

Experimental Example 4

Skin irritation evaluation]

After wiping the test site with 70% ethanol and drying the test site, 15 μL of each of the four compositions of Examples 1 and 16 and Comparative Examples 4 and 5 was applied to a Finn chamber and then fixed with Plaster. After 24 hours, the Finn chamber was removed, and after 30 minutes, the test site was scored according to the criteria of Table 4, and the results are shown in FIG. 4.

score	Criteria
0	Normal skin, no inflammation
0.5	Suspected of slight inflammatory reaction
One	Weak erythema
2	Normal erythema with or without partial edema or papules
3	Normal erythema with widespread edema
4	Strong erythema with vesicles and widespread edema

As shown in Figure 4, the composition of the present invention, while increasing the absorption of the active ingredient, it can be seen that there is little irritation to the skin compared to Comparative Examples 4 and 5.

Claims (17)

1. a) at least one nonsteroidal anti-inflammatory analgesic active ingredient,

   b) film forming materials,

   c) C8-C24 fatty acid alcohols,

   d) surfactants, and

   e) Film forming pharmaceutical composition comprising C2 ~ C4 alcohol having a boiling point of 100 ° C. or less.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is prepared in the form of a liquid, gel or ointment.
3. The method of claim 1, wherein the film forming material is composed of chitosan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl acetal diethyl amino acetate, polyvinylacetate graft copolymer and polyvinyl alcohol Pharmaceutical composition, characterized in that at least one selected from the group.
4. The pharmaceutical composition of claim 3, wherein the film forming material is included in an amount of 2 to 20 wt% based on the total weight of the composition.
5. 2. The nonsteroidal anti-inflammatory analgesic active ingredient according to claim 1, wherein the nonsteroidal anti-inflammatory analgesic active ingredient is selected from the group consisting of ketoprofen, diclofenac, pullulbipropene, roxofene, pyroxhamm, ibuprofen, and pharmaceutically acceptable salts thereof. Pharmaceutical composition, characterized in that at least one is selected.
6. According to claim 1, wherein the C8 ~ C24 fatty alcohol is a pharmaceutical composition, characterized in that at least one selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol and behenyl alcohol .
7. The pharmaceutical composition of claim 6, wherein the C8 to C24 fatty acid alcohol is included in an amount of 0.1 to 10 wt% based on the total weight of the composition.
8. The pharmaceutical composition of claim 1, wherein the surfactant is a nonionic surfactant.
9. The pharmaceutical composition of claim 8, wherein the nonionic surfactant is selected from the group consisting of polyoxyl castor oil, polysorbate and poloxamer.
10. The pharmaceutical composition of claim 8, wherein the surfactant is included in an amount of 0.005 to 10 parts by weight based on 1 part by weight of the active ingredient.
11. The pharmaceutical composition according to claim 10, wherein the surfactant is included in a ratio of 0.01 to 5 parts by weight based on 1 part by weight of the active ingredient.
12. According to claim 1, wherein the C2 ~ C4 alcohol is a pharmaceutical composition, characterized in that at least one selected from the group consisting of ethanol, 1-propanol and 2-propanol.
13. The pharmaceutical composition of claim 12, wherein the C2 to C4 alcohol is included in an amount of 10 to 90% by weight based on the total weight of the composition.
14. The pharmaceutical composition of claim 13, wherein the C 2 to C 4 alcohol is included in an amount of 30 to 90 wt% based on the total weight of the composition.
15. The pharmaceutical composition of claim 1, wherein the composition forms a film when applied to the skin or affected part, is free of skin irritation, and promotes drug absorption.
16. a) at least one nonsteroidal anti-inflammatory analgesic active ingredient,

    b) at least one film forming material selected from the group consisting of chitosan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylacetal diethylamino acetate, polyvinylacetate graft copolymer and polyvinyl alcohol ,

    c) C8 to C24 fatty acid alcohol selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol and behenyl alcohol,

    d) nonionic surfactants selected from the group consisting of polyoxyl castor oils, polysorbates, and poloxamers, and

    e) Film forming pharmaceutical composition, characterized in that it comprises a C2 ~ C4 alcohol having a boiling point of 100 ° C. or less.
17. a) a nonsteroidal anti-inflammatory analgesic active ingredient selected from the group consisting of ketoprofen, diclofenac, pullulbipropene, roxofene, pyroxicam, ibuprofen and salts thereof,

    b) at least one film forming material selected from the group consisting of chitosan, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylacetal diethylamino acetate, polyvinylacetate graft copolymer and polyvinyl alcohol ,

    c) C8 to C24 fatty alcohols selected from the group consisting of lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol and behenyl alcohol,

    d) nonionic surfactants selected from the group consisting of polyoxyl castor oils, polysorbates and poloxamers, and

    e) Film forming pharmaceutical composition, characterized in that it comprises a C2 ~ C4 alcohol having a boiling point of 100 ° C. or less.

Images